Abstract:The activation of caspases is a crucial event and an indicator of programmed cell death, also known as apoptosis. These enzymes play a central role in cancer biology and are considered one promising target for current and future advancements in therapeutic interventions. Traditional methods of measuring caspase activity such as antibody-based methods provide fundamental insights into their biological functions, and are considered essential tools in the fields of cell and cancer biology, pharmacology and toxicology, and drug discovery. However, traditional methods, though extensively used, are now recognized as having various shortcomings. In addition, these methods fall short of providing solutions to and matching the needs of the rapid and expansive progress achieved in studying caspases. For these reasons, there has been a continuous improvement in detection methods for caspases and the network of pathways involved in their activation and downstream signaling. Over the past decade, newer methods based on cutting-edge state-of-the-art technologies have been introduced to the biomedical community. These methods enable both the temporal and spatial monitoring of the activity of caspases and their downstream substrates, and with enhanced accuracy and precision. These include fluorescent-labeled inhibitors (FLIs) for live imaging, single-cell live imaging, fluorescence resonance energy transfer (FRET) sensors, and activatable multifunctional probes for in vivo imaging. Recently, the recruitment of mass spectrometry (MS) techniques in the investigation of these enzymes expanded the repertoire of tools available for the identification and quantification of caspase substrates, cleavage products, and post-translational modifications in addition to unveiling the complex regulatory networks implicated. Collectively, these methods are enabling researchers to unravel much of the complex cellular processes involved in apoptosis, and are helping generate a clearer and comprehensive understanding of caspase-mediated proteolysis during apoptosis. Herein, we provide a comprehensive review of various assays and detection methods as they have evolved over the years, so to encourage further exploration of these enzymes, which should have direct implications for the advancement of therapeutics for cancer and other diseases.

Caspase inhibitors: a review on recently patented compounds (2016-2023)

Progress in Caspases inhibitors research

A Review on Caspases: Key Regulators of Biological Activities and Apoptosis

The concealed side of caspases: beyond a killer of cells

Caspase-Mediated Programmed Cell Death Pathways As Potential Therapeutic Targets in Cancer

Caspase‐driven cancer therapies: Navigating the bridge between lab discoveries and clinical applications

The Role of Caspase Family in Acute Brain Injury: the Potential Therapeutic Targets in the Future

Therapeutic cysteine protease inhibitors: a patent review (2018–present)

Old, new and emerging functions of caspases

An updated patent review of Akt inhibitors (2016-present)

An update on the therapeutic potential of calpain inhibitors: a patent review

Cathepsin B and L Inhibitors: a Patent Review (2010 - Present).

How does caspases regulation play role in cell decisions? apoptosis and beyond

Protein kinase C inhibitors: a patent review (2010 - present)

From Classical Approaches to Cutting-Edge Innovations

Patenting perspective of modulators of ClpP endopeptidase: 2019-present

THE CASPASE FAMILY: MOLECULAR BASES OF INTERACTION IN APOPTOSIS AND PYROPTOSIS

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)

Calpain Inhibitors as Potential Therapeutic Modulators in Neurodegenerative Diseases